ATE233727T1 - 1,3-disubstituierte harnstoffe als acat- inhibitoren, sowie verfahren zu deren herstellung - Google Patents

1,3-disubstituierte harnstoffe als acat- inhibitoren, sowie verfahren zu deren herstellung

Info

Publication number
ATE233727T1
ATE233727T1 AT98961715T AT98961715T ATE233727T1 AT E233727 T1 ATE233727 T1 AT E233727T1 AT 98961715 T AT98961715 T AT 98961715T AT 98961715 T AT98961715 T AT 98961715T AT E233727 T1 ATE233727 T1 AT E233727T1
Authority
AT
Austria
Prior art keywords
disubstituted ureas
production
acat inhibitors
isocyanates
enzyme
Prior art date
Application number
AT98961715T
Other languages
English (en)
Inventor
Vladimir Oremus
Vendelin Smahovsky
Viera Faberova
Ivan Kakalik
Ludmila Schmidtova
Marian Zemanek
Original Assignee
Slovakofarma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slovakofarma As filed Critical Slovakofarma As
Application granted granted Critical
Publication of ATE233727T1 publication Critical patent/ATE233727T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • C07C323/44X or Y being nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
AT98961715T 1997-12-19 1998-12-16 1,3-disubstituierte harnstoffe als acat- inhibitoren, sowie verfahren zu deren herstellung ATE233727T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SK1751-97A SK282727B6 (sk) 1997-12-19 1997-12-19 1,3-Disubstituované močoviny - inhibítory ACAT a spôsob ich prípravy
PCT/SK1998/000019 WO1999032437A1 (en) 1997-12-19 1998-12-16 1,3-disubstituted ureas as acat inhibitors, and method of preparing thereof

Publications (1)

Publication Number Publication Date
ATE233727T1 true ATE233727T1 (de) 2003-03-15

Family

ID=20434795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961715T ATE233727T1 (de) 1997-12-19 1998-12-16 1,3-disubstituierte harnstoffe als acat- inhibitoren, sowie verfahren zu deren herstellung

Country Status (18)

Country Link
US (1) US6444691B1 (de)
EP (1) EP1042278B1 (de)
JP (1) JP2001526259A (de)
AT (1) ATE233727T1 (de)
AU (1) AU1697699A (de)
BG (1) BG104537A (de)
CZ (1) CZ299695B6 (de)
DE (1) DE69811949T2 (de)
DK (1) DK1042278T3 (de)
ES (1) ES2194379T3 (de)
HR (1) HRP20000351B1 (de)
HU (1) HUP0004332A3 (de)
PL (1) PL341235A1 (de)
PT (1) PT1042278E (de)
RU (1) RU2216536C2 (de)
SK (1) SK282727B6 (de)
WO (1) WO1999032437A1 (de)
YU (1) YU35100A (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2003209118A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005068420A1 (en) * 2003-12-23 2005-07-28 Esperion Therapeutics, Inc. Urea and thiourea compounds and compositions for cholesterol management and related uses
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
EP1814875A4 (de) 2004-10-20 2010-02-17 Univ California Verbesserte inhibitoren der löslichen epoxidhydrolase
SK287385B6 (sk) 2007-11-27 2010-08-09 Hameln-Rds, A. S. 1,3-Disubstituované močoviny, spôsob ich prípravy a použitia
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
CA2791680A1 (en) * 2010-03-01 2011-09-09 Myrexis, Inc. Compounds and therapeutic uses thereof
RU2486893C1 (ru) * 2012-06-13 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный технический университет" (ВолгГТУ) Способ получения бис[3-метил(адамант-1-ил)]мочевин
CN107417478B (zh) * 2017-06-05 2020-05-05 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
CN115677660B (zh) * 2022-10-27 2024-05-03 中国药科大学 苯基脲类化合物及其制备方法、用途和药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284433A (en) * 1963-07-17 1966-11-08 Merck & Co Inc 4-phenoxy-carbanilides
FR1593586A (de) * 1967-10-17 1970-06-01
DE2246109A1 (de) * 1972-09-20 1974-03-28 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JP2720053B2 (ja) * 1988-11-09 1998-02-25 チッソ株式会社 新規なジアミノ化合物、ジニトロ化合物、ジオール化合物および製造方法
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
US5576335A (en) 1994-02-01 1996-11-19 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as ACAT inhibitors
JP3668266B2 (ja) 1994-02-01 2005-07-06 株式会社日清製粉グループ本社 尿素誘導体
CA2161376C (en) 1994-10-27 2005-01-11 Toshiaki Minami Reversible multi-color thermal recording medium

Also Published As

Publication number Publication date
AU1697699A (en) 1999-07-12
HRP20000351B1 (en) 2003-10-31
HUP0004332A3 (en) 2002-11-28
RU2216536C2 (ru) 2003-11-20
DK1042278T3 (da) 2003-06-30
US6444691B1 (en) 2002-09-03
DE69811949D1 (de) 2003-04-10
EP1042278B1 (de) 2003-03-05
CZ299695B6 (cs) 2008-10-22
BG104537A (en) 2000-12-29
PL341235A1 (en) 2001-03-26
SK175197A3 (en) 1999-07-12
HUP0004332A2 (hu) 2001-05-28
WO1999032437A1 (en) 1999-07-01
CZ20002297A3 (cs) 2000-11-15
DE69811949T2 (de) 2004-03-04
HRP20000351A2 (en) 2000-12-31
SK282727B6 (sk) 2002-11-06
PT1042278E (pt) 2003-07-31
YU35100A (sh) 2002-10-18
JP2001526259A (ja) 2001-12-18
EP1042278A1 (de) 2000-10-11
ES2194379T3 (es) 2003-11-16

Similar Documents

Publication Publication Date Title
ATE233727T1 (de) 1,3-disubstituierte harnstoffe als acat- inhibitoren, sowie verfahren zu deren herstellung
ATE642T1 (de) Verfahren zur herstellung von urethanen.
DE69629670D1 (de) Lactam-enthaltende hydroxamsäure-derivate, deren herstellung und deren verwendung als inhibitoren von matrix-metalloproteasen
KR950025049A (ko) 폴리우레탄 제조용 히드록시-작용성 트리아민 촉매 조성물
DE60326245D1 (de) Verfahren zur herstellung von polyurethanschaumstoff
PT83172B (pt) Processo para a preparacao de inibidores de renina polipeptidicos contendo residuos do acido 5-amino-2,5-disubstituidos-4-hidroxipentanoico
BR9400011A (pt) Processo para catalisar a trimerização de um isocianato e/ou a reação de um isocianato e um composto contendo um hidrogênio reagente, processo para preparar espuma de poliuretano, e composição de catalisador
DE50004300D1 (de) Verfahren zur Umsetzung einer ein Gemisch enthaltenden Lösung
DE69425940T2 (de) Enzymatische synthese von ceramiden und hybrid-ceramiden
ATE408635T1 (de) Verfahren zur änderung von polyurethanschaumeigenschaften
DE59907222D1 (de) Verfahren zur herstellung von geschäumten polyisocyanat-polyadditionsprodukten oder polyurethanelastomeren unter verwendung von mischungen enthaltend isocyanate sowie organische und/oder anorganische säureanhydride
DE59600384D1 (de) Verfahren zur herstellung von biuretgruppen-haltigen polyisocyanaten
DE50008507D1 (de) Mischung von pflanzenbehandlungsmitteln mit wachsen, verfahren zu deren herstellung und deren verwendung
DE50212185D1 (de) Verfahren zur herstellung von isocyanaten
DE59607733D1 (de) Verfahren zur herstellung von organischen diurethanen und/oder polyurethanen und ihre verwendung zur herstellung von di- und/oder polyisocyanaten
ATE226597T1 (de) Verfahren zur herstellung von cellulosecarbamat
DE59800587D1 (de) Verfahren zur Herstellung von Polyurethan-Weichschaumstoffen
ATE60057T1 (de) Verfahren zur herstellung von hexamethylcyclotrisilazan.
BR9500675A (pt) Processo para catalisar a reação de um poliisocianato consigo mesmo ou com um composto contendo hidrogênio ativo processo para preparação de espuma de poliuretano e composição de catalisador
ATE289T1 (de) Verfahren zur herstellung von urethanen.
DE60115403D1 (de) Kontinuierliches verfahren zur herstellung von aromatischen urethanen
ATE53223T1 (de) Verfahren zur herstellung von polyaminen.
DE59908915D1 (de) Verfahren zur herstellung von diarylcarbonaten
DK1002100T3 (da) Fremgangsmåde til fremstilling og identifikation af nye hydrolaser med forbedrede egenskaber
SU1811161A1 (ru) Способ получения органических изоцианатов

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1042278

Country of ref document: EP

REN Ceased due to non-payment of the annual fee